Now Dispensing INREBIC®

August 16, 2019

Now Dispensing INREBIC®

Onco360 is privileged to be selected as a specialty pharmacy provider for Celgene’s new product INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF).

“Onco360 is privileged to be selected as a specialty pharmacy provider for INREBIC patients,” said Paul Jardina, President and CEO, Onco360. “The recent approval of INREBIC provides another treatment options for patients with newly-diagnosed MF while providing a novel treatment option for MF patients who have experienced failure with ruxolitinib as a result of lack of tolerance or response. As a provider of INREBIC treatment, Onco360 will utilize its expertise in the delivery of clinical oncology and hematology programs through it high-touch patient support model designed for the highly specialized needs of MF patients and their physicians.”

Myelofibrosis is considered a form of chronic leukemia. It is a serious and rare bone marrow disorder that disrupts the body’s normal production of blood cells. Bone marrow is gradually replaced with fibrous scar tissue, which limits the ability of the bone marrow to make red blood cells. The disorder can lead to weakness, fatigue and swelling of the spleen and liver, among other symptoms. Myelofibrosis is classified as a myeloproliferative neoplasm, a group of rare blood cancers that derive from blood-forming stem cells. In the U.S., myelofibrosis occurs in 1.5 of every 100,000 people each year. Both men and women are affected, and while the disease can affect people of all ages, the median age at diagnosis ranges from 60 to 67 years. On average, MF patients survive five to six years following their initial diagnosis. In the absence of treatment, up to 12% of MF patients will progress and develop Acute Myeloid Leukemia (AML).

INREBIC obtained FDA approval as a result of the randomized, Phase III JAKARTA trial, which demonstrated that INREBIC administration resulted in significantly improved MF-associated symptom burden (40% vs. 9%) and significantly improved spleen response rates (37% vs. 1%) compared to a placebo.

INREBIC is manufactured by Celgene Corporation and was approved by the U.S. FDA on August 16, 2019. See full Prescribing Information.

INREBIC is now available to order through Onco360.